Plantar fascial fibromatosis, also called Ledderhose disease, is a condition in which firm, slow-growing nodules develop within the thick band of tissue on the sole of your foot. These nodules are made up of fibroblasts and related cells that proliferate abnormally in the plantar fascia, the connective tissue that runs from your heel to the base of your toes. The condition is benign, meaning the growths are not cancerous, but they can become painful enough to interfere with walking. What drives this overgrowth is still not entirely clear, and treatment ranges from simple shoe inserts to surgery depending on how much trouble the nodules cause.
What Happens Inside the Foot
The plantar fascia is a broad, flat ligament that supports your foot’s arch and absorbs shock with every step. In plantar fibromatosis, clusters of spindle-shaped cells begin multiplying within this tissue, forming one or more firm lumps. A review in the Journal of Pathology and Translational Medicine describes these growths as a “bland cellular proliferation of spindle cells” embedded in varying amounts of collagen, with younger lesions being more cellular and older ones becoming more fibrous and collagen-heavy.1PubMed Central. Palmar and plantar fibromatosis: a review Unlike Dupuytren’s disease in the hand, which is a close biological relative, plantar fibromatosis rarely causes the fingers-curling-inward contracture that hand patients experience. Instead, the main problem is the physical lump pressing against the ground every time you take a step.
Most nodules appear along the medial (inner) arch of the foot, attached to the central band of the plantar fascia. They are usually anchored to the fascia itself rather than floating freely in the surrounding tissue, which is why they feel hard and immovable when you press on them.2PubMed Central. Combination Hyaluronidase and Triamcinolone Acetonide Enzymatic Injections for Treatment of Ledderhose Disease: A Novel Technique and Case Series Some people develop a single nodule; others develop several, sometimes in both feet.
Who Gets It and What the Symptoms Feel Like
Plantar fibromatosis can show up at any age, but it is most common in middle-aged and older adults, and it occurs more often in men than in women.3PubMed Central. Ledderhose disease: an unusual presentation That said, younger patients are not immune. One case report describes a 32-year-old woman who developed three painful nodules on her left sole over six months.4PubMed Central. The Surgical Treatment of Plantar Fibromatosis With Multiple Large Nodules on the Medial Aspect of the Left Sole With No Recurrence at the Five-Year Follow-Up
In its early stages, you might notice a small, painless lump on the sole of your foot, often near the highest point of the arch. Many people first feel it while walking barefoot on a hard surface. Over time, the nodules can enlarge and become tender, especially under pressure from standing, walking, or wearing tight shoes. As the disease advances, the pain and inflammation along the medial plantar surface can disrupt your normal gait, because any distortion of the plantar fascia changes how your foot rolls and pushes off during each step.5Foot and Ankle Surgery. Soleful solutions: Advancements in treatment strategies for ledderhose disease People sometimes start favoring the other foot or adjusting their stride to avoid stepping on the lump, which can lead to knee, hip, or back pain over time.
Known Causes and Risk Factors
The honest answer is that nobody has pinpointed a single cause. The condition’s origins remain partially mysterious, though a cluster of associated risk factors has emerged from clinical observation. A comprehensive review in Clinics and Practice lists the most frequently reported associations: diabetes, use of anticonvulsant medications, frozen shoulder, alcohol consumption, liver disease, and repeated trauma to the foot.6PubMed Central. Ledderhose’s Disease: An Up-to-Date Review of a Rare Non-Malignant Disorder Smoking has also been linked to the condition.7Irish Medical Journal. Bilateral Plantar Fibromatosis
A genetic component is strongly suspected, in part because plantar fibromatosis frequently overlaps with other fibroproliferative conditions. In a study of 730 men with Dupuytren’s disease (the hand equivalent), about one in five to one in six also had Ledderhose disease, depending on whether the diagnosis came from a surgeon’s exam or the patient’s own report.8PubMed. Prevalence of Peyronie and Ledderhose Diseases in a Series of 730 Patients with Dupuytren Disease That overlap hints at a shared underlying tendency toward abnormal fibroblast behavior in connective tissues throughout the body, rather than a problem unique to the foot. Researchers have also found families where multiple members develop these fibromatoses, sometimes alongside seemingly unrelated conditions like genetic heart disease, suggesting that certain inherited mutations may predispose connective tissue to this kind of overgrowth.9PubMed Central. Dupuytren’s and Ledderhose Diseases in a Family with LMNA-Related Cardiomyopathy and a Novel Variant in the ASTE1 Gene
None of these associations, though, should be read as “if you have diabetes, you will get plantar fibromatosis.” Many people with every listed risk factor never develop the condition, and some patients have none of the known risk factors at all. The associations simply indicate terrain where clinicians should have a higher index of suspicion if a patient shows up with a lump on the sole of the foot.
How It Is Diagnosed
Most of the time, a doctor can suspect plantar fibromatosis based on the physical exam alone: a firm, immovable nodule on the medial arch, attached to the plantar fascia, without any overlying skin changes. But imaging is helpful for confirming the diagnosis, measuring the nodule, and ruling out the rare possibility of something more serious like a soft-tissue sarcoma.
Ultrasound is the most common first-line imaging tool. On ultrasound, plantar fibromatosis typically shows up as a discrete, spindle-shaped thickening of the plantar fascia, separate from the heel bone insertion. In one study, about three-quarters of lesions appeared hypoechoic (darker than surrounding tissue), most were well-defined, and the vast majority showed no abnormal blood flow inside.10PubMed. Sonography of plantar fibromatosis Lesions are usually elongated along the length of the foot, and most measure under two centimeters. Larger nodules tend to have mixed echogenicity, meaning they have some brighter spots mixed in with the darker tissue.11PubMed. Plantar fibromatosis: most common sonographic appearance and variations
MRI provides more detail when the diagnosis is unclear or surgery is being considered. On MRI, the nodules typically appear dark on most standard imaging sequences, which reflects their dense collagen content.12PubMed Central. Imaging of plantar fascia disorders: findings on plain radiography, ultrasound and magnetic resonance imaging A large recent series from a tertiary care center found that about two-thirds of lesions were heterogeneous in signal, meaning they looked uneven internally, and roughly the same proportion showed enhancement after contrast dye was injected. Only a small fraction, under ten percent, had areas of cystic change inside.13PubMed. MRI characteristics of plantar fibromas: a large consecutive series from a tertiary care center with symptom analysis That heterogeneity can occasionally mimic more aggressive tumors on a first glance, which is one reason radiologists look at the overall pattern and location rather than any single feature.
Conservative Treatment Options
Because plantar fibromatosis is benign and often progresses slowly, the first line of treatment is almost always conservative. The goal is not to eliminate the nodule but to reduce the pain it causes so you can walk and stand comfortably. Podiatric interventions like custom orthotics, footwear modifications, and manual therapy form the foundation of this approach.14PubMed Central. The Role of Podiatric Treatment in Ledderhose Disease Management A well-designed orthotic can redistribute pressure away from the nodule, and simply switching to shoes with a wider, more cushioned sole makes a meaningful difference for many patients.
When basic physical measures are not enough, several injectable and procedural treatments have been tried:
- Steroid injections: Corticosteroids injected directly into the nodule can shrink it temporarily and reduce inflammation. This is one of the most widely used medical treatments, though the effects can wear off and repeated injections carry their own risks, including thinning of the fat pad on the sole.
- Verapamil: This calcium channel blocker, typically used for heart conditions, has been tried as a topical or injectable treatment to slow fibroblast activity. Evidence for its effectiveness in plantar fibromatosis is limited and mostly based on small case series.
- Shockwave therapy: Extracorporeal shockwave therapy delivers focused acoustic energy to the nodule. In a small study, patients started with an average pain score of 6 out of 10, which dropped to 2 after two weeks and 1 after three months, with all patients reporting softening of their nodules.15PubMed Central. High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis (Ledderhose’s disease) Another case report documented complete pain relief and full return to activity after a shockwave protocol for bilateral disease.16PubMed Central. Pain-Relieving Effects of Shockwave Therapy for Ledderhose Disease: An Ultrasound-Based Study of an Unusual Bilateral Case
- Combination enzymatic injections: A newer approach combines hyaluronidase with a steroid (triamcinolone) to both break down tissue and reduce inflammation. Early case series report promising results, though long-term data is still thin.2PubMed Central. Combination Hyaluronidase and Triamcinolone Acetonide Enzymatic Injections for Treatment of Ledderhose Disease: A Novel Technique and Case Series
Radiation Therapy for Early-Stage Disease
One treatment that surprises many patients is low-dose radiation therapy. It sounds aggressive for a benign condition, but radiotherapy has a track record in European practice for early-stage Ledderhose disease, particularly in Germany where it has been used for decades. The idea is to irradiate the nodules at low doses to prevent the fibroblasts from continuing to multiply.
In one study, patients were treated with radiation and followed for a median of about two years. None experienced progression of their nodules or worsening symptoms. About a third achieved complete remission of their nodules, over half had a reduced number or size of lesions, and the remainder stayed stable. No significant skin or soft-tissue side effects were reported.17PubMed. Radiation therapy for early stages of morbus Ledderhose These results are encouraging, though the study was small and follow-up was relatively short. Radiation therapy works best when the disease is still in an early or moderately active phase. Once nodules have become large, dense, and heavily collagenized, radiation is less likely to produce meaningful shrinkage. In some cases, radiation effectively delays the need for surgery even if it does not eliminate the nodules permanently.18International Journal of Innovative Science and Research Technology (IJISRT). Radiation Therapy of a Case of Ledderhose’s Disease: A Rare Benign Nodule of the Plantar Aponeurosis
The main concern patients raise about radiation for a non-cancerous condition is long-term risk. The doses used are quite low compared to cancer treatment, but any radiation exposure carries a theoretical risk of secondary malignancy over decades. This is typically discussed as part of informed consent, especially for younger patients who have the most years of potential risk ahead of them.
When Surgery Becomes Necessary
Surgery is generally reserved for patients whose pain and functional limitations persist despite a reasonable trial of conservative measures. In the case of the 32-year-old woman mentioned earlier, anti-inflammatory drugs, stretching, orthotic insoles, and physiotherapy all failed to control her symptoms, and she ultimately underwent partial plantar fasciectomy, the removal of the affected portion of the plantar fascia along with the nodules. Pathology confirmed the diagnosis, and at five years of follow-up she remained pain-free with no recurrence.4PubMed Central. The Surgical Treatment of Plantar Fibromatosis With Multiple Large Nodules on the Medial Aspect of the Left Sole With No Recurrence at the Five-Year Follow-Up
That case, though, represents an excellent outcome. Recurrence after surgery is the major drawback of operative treatment, and the rates vary dramatically depending on how much tissue is removed. A systematic review and case series found the following pattern: local excision of the nodule alone had a recurrence rate of about 67 percent, wider excision brought it down to around 42 percent, and complete fasciectomy (removing the entire plantar fascia) had the lowest rate, roughly 27 percent.19PubMed. Recurrence Rate After Wide Resection of Plantar Fibromatosis: A Case Series and Systematic Literature Review A separate long-term study put the overall recurrence rate even higher, at 60 percent across all surgical types, with total fasciectomy still performing best at 25 percent recurrence and local excision worst at 100 percent recurrence.20PubMed. Recurrence of plantar fibromatosis after plantar fasciectomy: single-center long-term results
The same study noted that having multiple nodules in one foot seemed to predict a higher recurrence rate, and that adding postoperative radiation therapy to fasciectomy appeared to lower the chance of the nodules returning compared to surgery alone.20PubMed. Recurrence of plantar fibromatosis after plantar fasciectomy: single-center long-term results This is one area where clinical judgment matters a lot: a surgeon deciding how aggressively to resect has to weigh the lower recurrence rate of a total fasciectomy against the functional consequences of removing a structure that supports your entire arch.
Collagenase Injections as an Emerging Treatment
Collagenase clostridium histolyticum, an enzyme that digests collagen, has been used for years to treat Dupuytren’s contracture in the hand. Researchers have been investigating whether it could also work for plantar fibromatosis. A phase 2 trial compared collagenase injections to placebo in patients with plantar fibromas and found that the treated group had significant improvements in pain scores, difficulty with daily activities, overall clinical impression of change, and both the hardness and consistency of the nodules.21PubMed Central. Collagenase Clostridium Histolyticum (CCH) in Patients with Plantar Fibromatosis (PFI): Post Hoc Analysis of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study No serious adverse events were reported. This is still early-stage research, and collagenase is not yet a standard treatment for plantar fibromatosis, but it represents one of the more rigorous attempts to develop a non-surgical option that actually targets the tissue composition of the nodule rather than just managing symptoms.
The Overlap With Other Fibromatoses
If you have been diagnosed with plantar fibromatosis, your doctor may ask about lumps in your palms or other symptoms that seem unrelated to your feet. That is because Ledderhose disease belongs to a family of fibroproliferative conditions that share a common cellular mechanism. Dupuytren’s disease in the hand is the most well-known relative, and the two conditions are histologically similar, composed of the same type of spindle cell proliferation.1PubMed Central. Palmar and plantar fibromatosis: a review Peyronie’s disease, which causes fibrous plaques in penile tissue, is another member of this family. Among men with Dupuytren’s disease, roughly 8 to 9 percent also have Peyronie’s disease, and 16 to 22 percent also have Ledderhose disease.8PubMed. Prevalence of Peyronie and Ledderhose Diseases in a Series of 730 Patients with Dupuytren Disease
This clustering matters practically, not just academically. If you develop one of these conditions, being aware of the others means you can flag a new lump early rather than ignoring it for years. It also means that treatment strategies proven in one condition sometimes get tested in the others, which is exactly how collagenase injections migrated from Dupuytren’s research to plantar fibromatosis trials.
Living With Plantar Fibromatosis
For many people, plantar fibromatosis is a nuisance rather than a crisis. Small, painless nodules may never require any treatment at all. When the condition does cause problems, it tends to do so gradually, giving you time to try conservative approaches before escalating. The practical adjustments that help most are straightforward: shoes with extra cushioning and a roomy toe box, accommodative insoles that offload the arch, and avoiding barefoot walking on hard floors.
What can be frustrating is that, unlike a broken bone or a torn ligament, there is no treatment that reliably makes plantar fibromatosis go away permanently. Even total fasciectomy, the most aggressive surgical option, still leaves roughly one in four patients with a recurrence. The disease seems to reflect something inherent in the patient’s connective tissue biology rather than a one-time injury that can be definitively fixed. That is why many specialists recommend exhausting conservative options before turning to surgery, and why emerging treatments like collagenase and shockwave therapy are generating real interest: they offer a middle ground between doing nothing and removing a structurally important piece of your foot.
Patients with bilateral disease or a family history of fibromatosis conditions tend to have a more stubborn course, and they are usually the ones who cycle through multiple treatments over the years. If you fall into that category, working with a foot and ankle specialist who has specific experience with plantar fibromatosis, rather than treating it as just another foot lump, can make a real difference in how your care is managed over time.